186 related articles for article (PubMed ID: 27484730)
21. Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma.
Lau CK; Yang ZF; Lam SP; Lam CT; Ngai P; Tam KH; Poon RT; Fan ST
Cancer Biol Ther; 2007 Dec; 6(12):1900-7. PubMed ID: 18059167
[TBL] [Abstract][Full Text] [Related]
22. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
[TBL] [Abstract][Full Text] [Related]
23. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities.
Zhang J; Li J; Shi Z; Yang Y; Xie X; Lee SM; Wang Y; Leong KW; Chen M
Acta Biomater; 2017 Aug; 58():349-364. PubMed ID: 28455219
[TBL] [Abstract][Full Text] [Related]
24. Doxorubicin and rhein loaded nanomicelles attenuates multidrug resistance in human ovarian cancer.
Han NN; Li X; Tao L; Zhou Q
Biochem Biophys Res Commun; 2018 Mar; 498(1):178-185. PubMed ID: 29317204
[TBL] [Abstract][Full Text] [Related]
25. EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma.
Dong Q; Du Y; Li H; Liu C; Wei Y; Chen MK; Zhao X; Chu YY; Qiu Y; Qin L; Yamaguchi H; Hung MC
Cancer Res; 2019 Feb; 79(4):819-829. PubMed ID: 30573522
[TBL] [Abstract][Full Text] [Related]
26. Reversal effect of quercetin on multidrug resistance via FZD7/β-catenin pathway in hepatocellular carcinoma cells.
Chen Z; Huang C; Ma T; Jiang L; Tang L; Shi T; Zhang S; Zhang L; Zhu P; Li J; Shen A
Phytomedicine; 2018 Apr; 43():37-45. PubMed ID: 29747752
[TBL] [Abstract][Full Text] [Related]
27. Bevacizumab and CCR2 Inhibitor Nanoparticles Induce Cytotoxicity-Mediated Apoptosis in Doxorubicin-Treated Hepatic and Non-Small Lung Cancer Cells.
Abd-Rabou AA; Ahmed HH
Asian Pac J Cancer Prev; 2019 Jul; 20(7):2225-2238. PubMed ID: 31350989
[TBL] [Abstract][Full Text] [Related]
28. Cystathionine β-synthase Induces Multidrug Resistance and Metastasis in Hepatocellular Carcinoma.
Wang L; Han H; Liu Y; Zhang X; Shi X; Wang T
Curr Mol Med; 2018; 18(7):496-506. PubMed ID: 30539696
[TBL] [Abstract][Full Text] [Related]
29. Facile synthesis of aquo-cisplatin arsenite multidrug nanocomposites for overcoming drug resistance and efficient combination therapy.
Xin J; Zhang K; Huang J; Luo X; Gong X; Yang Z; Lin H; Shan H; Gao J
Biomater Sci; 2018 Dec; 7(1):262-271. PubMed ID: 30465673
[TBL] [Abstract][Full Text] [Related]
30. Intratumoral Administration of Thermosensitive Hydrogel Co-Loaded with Norcantharidin Nanoparticles and Doxorubicin for the Treatment of Hepatocellular Carcinoma.
Gao B; Luo J; Liu Y; Su S; Fu S; Yang X; Li B
Int J Nanomedicine; 2021; 16():4073-4085. PubMed ID: 34163160
[TBL] [Abstract][Full Text] [Related]
31. Synergism of hydroxyapatite nanoparticles and recombinant mutant human tumour necrosis factor-alpha in chemotherapy of multidrug-resistant hepatocellular carcinoma.
Li G; Dong S; Qu J; Sun Z; Huang Z; Ye L; Liang H; Ai X; Zhang W; Chen X
Liver Int; 2010 Apr; 30(4):585-92. PubMed ID: 19780956
[TBL] [Abstract][Full Text] [Related]
32. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin.
Zhang X; Li J; Yan M
Drug Dev Ind Pharm; 2016 Oct; 42(10):1590-9. PubMed ID: 26942448
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
[TBL] [Abstract][Full Text] [Related]
34. Co-delivery of DOX and PDTC by pH-sensitive nanoparticles to overcome multidrug resistance in breast cancer.
Cheng X; Li D; Sun M; He L; Zheng Y; Wang X; Tang R
Colloids Surf B Biointerfaces; 2019 Sep; 181():185-197. PubMed ID: 31132609
[TBL] [Abstract][Full Text] [Related]
35. Impact of arsenite and its methylated metabolites on PARP-1 activity, PARP-1 gene expression and poly(ADP-ribosyl)ation in cultured human cells.
Walter I; Schwerdtle T; Thuy C; Parsons JL; Dianov GL; Hartwig A
DNA Repair (Amst); 2007 Jan; 6(1):61-70. PubMed ID: 17011244
[TBL] [Abstract][Full Text] [Related]
36. Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrug-resistant HCC cell line HEPG2/ADM by RNA interference.
Li H; Zhou S; Li T; Liu Z; Wu J; Zeng G; Liu C; Gong J
Hepatogastroenterology; 2012 Oct; 59(119):2238-42. PubMed ID: 23435138
[TBL] [Abstract][Full Text] [Related]
37. Development and characterization of P-glycoprotein 1 (Pgp1, ABCB1)-mediated doxorubicin-resistant PLHC-1 hepatoma fish cell line.
Zaja R; Caminada D; Loncar J; Fent K; Smital T
Toxicol Appl Pharmacol; 2008 Mar; 227(2):207-18. PubMed ID: 18076962
[TBL] [Abstract][Full Text] [Related]
38. Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma.
Zheng T; Yin D; Lu Z; Wang J; Li Y; Chen X; Liang Y; Song X; Qi S; Sun B; Xie C; Meng X; Pan S; Liu J; Jiang H; Liu L
Mol Cancer; 2014 May; 13():133. PubMed ID: 24884809
[TBL] [Abstract][Full Text] [Related]
39. The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line.
Huang M; Liu G
Cancer Lett; 1999 Jan; 135(1):97-105. PubMed ID: 10077227
[TBL] [Abstract][Full Text] [Related]
40. Down-regulation of extracellular signal-regulated kinase 1/2 activity in P-glycoprotein-mediated multidrug resistant hepatocellular carcinoma cells.
Yan F; Wang XM; Pan C; Ma QM
World J Gastroenterol; 2009 Mar; 15(12):1443-51. PubMed ID: 19322916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]